Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for GMAB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 -1.255M
March 31, 2026 94.35M
December 31, 2025 -7.443M
September 30, 2025 13.50M
June 30, 2025 403.19M
March 31, 2025 -1.001M
December 31, 2024 0.4602M
September 30, 2024 37.99M
June 30, 2024 437.59M
March 31, 2024 70.75M
December 31, 2023 -2.113M
September 30, 2023 -5.577M
June 30, 2023 -6.581M
March 31, 2023 73.66M
December 31, 2022 -25.98M
September 30, 2022 87.86M
June 30, 2022 28.32M
March 31, 2022 -2.262M
December 31, 2021 -5.901M
September 30, 2021 -7.774M
June 30, 2021 35.78M
March 31, 2021 27.53M
December 31, 2020 -8.469M
September 30, 2020 -5.106M
June 30, 2020 -2.478M
Date Value
March 31, 2020 -5.456M
December 31, 2019 6.802M
September 30, 2019 -552.30M
June 30, 2019 -5.031M
March 31, 2019 -0.8198M
December 31, 2018 -0.343M
September 30, 2018 -2.363M
June 30, 2018 -7.133M
March 31, 2018 21.10M
December 31, 2017 -1.438M
September 30, 2017 -3.156M
June 30, 2017 -13.29M
March 31, 2017 -14.80M
December 31, 2016 -3.810M
September 30, 2016 2.502M
June 30, 2016 -6.637M
March 31, 2016 -5.681M
December 31, 2015 -7.316M
September 30, 2015 -18.18M
June 30, 2015 -22.87M
March 31, 2015 -47.86M
December 31, 2014 0.853M
September 30, 2014 -2.445M
June 30, 2014 -0.755M
March 31, 2014 -183.46M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 9.00M
Ascendis Pharma A/S 38.47M
Zealand Pharma A/S 66.43M
Bavarian Nordic A/S 34.93M
Evaxion AS 0.00